[1]American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S17-S38.
[2]Nayak A U, Singh B M, Dunmore S J. Potential clinical error arising from use of HbA1c in diabetes: effects of the glycation gap[J]. Endocr Rev, 2019, 40(4): 988-999.
[3]Hempe J M, Liu S, Myers L, et al. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial[J]. Diabetes Care, 2015, 38(6): 1067-1074.
[4]Soros A A, Chalew S A, McCarter R J, et al. Hemoglobin glycation index: a robust measure of hemoglobin A1c bias in pediatric type 1 diabetes patients[J]. Pediatr Diabetes, 2010, 11(7): 455-461.
[5]Marini M A, Fiorentino T V, Succurro E, et al. Association between hemoglobin glycation index with insulin resistance and carotid atherosclerosis in non-diabetic individuals[J]. PLoS One, 2017, 12(4): e0175547.
[6]Yoo J H, Kang Y M, Cho Y K, et al. The haemoglobin glycation index is associated with nonalcoholic fatty liver disease in healthy subjects[J]. Clin Endocrinol (Oxf), 2019, 91(2): 271-277.
[7]Fiorentino T V, Marini M A, Succurro E, et al. Association between hemoglobin glycation index and hepatic steatosis in non-diabetic individuals[J]. Diabetes Res Clin Pract, 2017, 134: 53-61.
[8]Wei Y, Wu Z Y, Wang Y, et al. Interaction of sex and diabetes on the association between hemoglobin glycation index, hemoglobin A1c and serum uric acid[J]. Diabetol Metab Syndr, 2022, 14(1): 185.
[9]McCarter R J, Hempe J M, Gomez R, et al. Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes[J]. Diabetes Care, 2004, 27(6): 1259-1264.
[10]Ahn C H, Min S H, Lee D H, et al. Hemoglobin glycation index is associated with cardiovascular diseases in people with impaired glucose metabolism[J]. J Clin Endocrinol Metab, 2017, 102(8): 2905-2913.
[11]Cheng P C, Hsu S R, Cheng Y C, et al. Relationship between hemoglobin glycation index and extent of coronary heart disease in individuals with type 2 diabetes mellitus: a cross-sectional study[J]. Peer J, 2017, 5: e3875.
[12]Rhee E J, Cho J H, Kwon H, et al. Association between coronary artery calcification and the hemoglobin glycation index: the kangbuk samsung health study[J]. J Clin Endocrinol Metab, 2017, 102(12): 4634-4641.
[13]World Health Organization. Hypertension[EB/OL]. (2021-08-25)[2022-12-01]. https://www.who.int/news-room/fact-sheets/detail/hypertension.
[14]中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3): 221-255.
[15]Levey A S, Stevens L A, Schmid C H, et al. A new equation to estimate glomerular filtration rate[J]. Ann Intern Med, 2009, 150(9): 604-612.
[16]Ebrahim S, Papacosta O, Whincup P, et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study[J]. Stroke, 1999, 30(4): 841-850.
[17]Li F R, Yang H L, Zhou R, et al. Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality[J]. Diabetes Obes Metab, 2021, 23(6): 1361-1370.
[18]OLeary D H, Polak J F, Kronmal R A, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults[J]. N Engl J Med, 1999, 340(1): 14-22.
[19]Felipe D L, Hempe J M, Liu S Q, et al. Skin intrinsic fluorescence is associated with hemoglobin A1c and hemoglobin glycation index but not mean blood glucose in children with type 1 diabetes[J]. Diabetes Care, 2011, 34(8): 1816-1820.
[20]Goldin A, Beckman J A, Schmidt A M, et al. Advanced glycation end products: sparking the development of diabetic vascular injury[J]. Circulation, 2006, 114(6): 597-605.
[21]Uribarri J, Cai W J, Ramdas M, et al. Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1[J]. Diabetes Care, 2011, 34(7): 1610-1616.
[22]Howard G, OLeary D H, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators[J]. Circulation, 1996, 93(10): 1809-1817.
[23]Cipollone F, Iezzi A, Fazia M, et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques[J]. Circulation, 2003, 108(9): 1070-1077.
[24]Song P G, Fang Z, Wang H Y, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study[J]. Lancet Glob Health, 2020, 8(5): e721-e729.
|